Ocular Therapeutix Q2 FY26 net loss widens to $78.76 million; revenue rises 0.12% to $13.48 million

Reuters2026/08/03 11:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ocular Therapeutix posted a Q2 net loss of $78.76 million, or $0.35 per share, widening from a $67.81 million loss a year earlier.
Revenue was $13.48 million, essentially flat versus the prior-year quarter, while R&D spending rose to $54.14 million.
Selling and marketing expense climbed to $17.28 million, while general and administrative costs increased to $22.16 million.
Cash and cash equivalents totaled $598.64 million at June 30, with runway expected into 2028.
AXPAXLI wet AMD NDA submission remains on track for Q4 2026 following FDA Type C meeting alignment; Ocular plans a 505(b)(2) filing that could shorten review by up to 60 days.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030700PRIMZONEFULLFEED9802251) on August 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ocular Therapeutix Q2 FY26 net loss widens to $78.76 million; revenue rises 0.12% to $13.48 million

You may also like

Crypto prices